Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alkermes (ALKS) EBT (2016 - 2026)

Alkermes has reported EBT over the past 16 years, most recently at $60.4 million for Q4 2025.

  • Quarterly EBT fell 64.46% to $60.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $291.4 million through Dec 2025, down 34.32% year-over-year, with the annual reading at $291.4 million for FY2025, 34.32% down from the prior year.
  • EBT was $60.4 million for Q4 2025 at Alkermes, down from $100.7 million in the prior quarter.
  • Over five years, EBT peaked at $281.8 million in Q2 2023 and troughed at -$67.4 million in Q3 2022.
  • The 5-year median for EBT is $59.3 million (2023), against an average of $60.7 million.
  • Year-over-year, EBT crashed 1310.54% in 2021 and then skyrocketed 947.61% in 2023.
  • A 5-year view of EBT shows it stood at $127.3 million in 2021, then fell by 10.04% to $114.5 million in 2022, then plummeted by 49.06% to $58.3 million in 2023, then surged by 191.32% to $169.9 million in 2024, then plummeted by 64.46% to $60.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALKS's EBT are $60.4 million (Q4 2025), $100.7 million (Q3 2025), and $104.8 million (Q2 2025).